NCT03723967View on ClinicalTrials.gov

FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

May 16, 2020

Study Completion Date

March 9, 2024

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Durvalumab with Carboplatin/Paclitaxel

Durvalumab associated with Carboplatin / Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy

Trial Locations (17)

13005

Hôpital de la Timone, Marseille

21079

Centre Georges-François Leclerc, Dijon

34298

ICM - Centre Val d'Aurelle, Montpellier

44277

Hôpital Privé du Confluent, Nantes

44600

Clinique Mutualiste de l'Estuaire, Saint-Nazaire

44805

ICO - Centre René Gauducheau, Saint-Herblain

54511

Institut de Cancérologie de Lorraine Alexis Vautrin, Vandœuvre-lès-Nancy

56322

Groupe hospitalier Bretagne Sud, Lorient

59055

ICO - Centre Paul Papin, Angers

67065

Centre Paul Strauss, Strasbourg

69004

Hôpital de la Croix-Rousse, Lyon

69008

Centre Léon Bérard, Lyon

76038

Centre Henri Becquerel, Rouen

76600

Clinique des Ormeaux, Le Havre

80054

CHU d'Amiens, Amiens

84918

Institut Sainte-Catherine, Avignon

94805

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

Centre Leon Berard

OTHER

NCT03723967 - FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel | Biotech Hunter | Biotech Hunter